Concurrent use of aromatase inhibitors and hypofractionated radiation therapy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

393

HTML

3303

Figures (1-1)

205

Tables (1-4)

195

Sum=4096

Jul 28, 2012 (publication date) through Nov 5, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Radiology

ISSN

1949-8470

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Radiol. Jul 28, 2012; 4(7): 318-323
Published online Jul 28, 2012. doi: 10.4329/wjr.v4.i7.318

Table 4 Reasons for discontinuating aromatase inhibitors therapy prior to 5 yr adjuvant therapy

Reasons for discontinuation	n (%)
Thromboembolic event	4 (6.0)
Progression	3 (4.5)
Patient death	5 (7.5)
Clinical intolerance	5 (7.5)
Total discontinuations	17 (25.5)

Citation: Chargari C, Castro-Pena P, Toledano I, Bollet MA, Savignoni A, Cottu P, Laki F, Campana F, Fourquet A, Kirova YM. Concurrent use of aromatase inhibitors and hypofractionated radiation therapy. World J Radiol 2012; 4(7): 318-323
URL: https://www.wjgnet.com/1949-8470/full/v4/i7/318.htm
DOI: https://dx.doi.org/10.4329/wjr.v4.i7.318